Wnt/Beta-Catenin: The Growth Pathway Every New Hair Drug Targets

If finasteride and minoxidil represent the first generation of hair loss pharmacology, Wnt pathway activators represent the second. Understanding the pathway explains what is coming.

Wnt/beta-catenin is arguably the most consequential signalling pathway in hair follicle biology. It is required for embryonic follicle formation, anagen initiation in adult cycling follicles, and DP inductive capacity maintenance. It is also the pathway targeted by the most promising next-generation investigational compounds in AGA drug development.

The pathway architecture

Wnt ligands (there are 19 in the human genome) are secreted glycoproteins that bind Frizzled receptors and their LRP5/6 co-receptors on target cells. This binding triggers intracellular signalling that inhibits the “destruction complex” — a multiprotein assembly including glycogen synthase kinase-3-beta (GSK-3β), APC, and axin — that normally tags beta-catenin for proteasomal degradation.

When Wnt is active, beta-catenin accumulates in the cytoplasm and enters the nucleus, where it acts as a co-activator with TCF/LEF transcription factors to drive expression of proliferative and follicle-developmental target genes. When Wnt is inactive, beta-catenin is constitutively degraded and these target genes are suppressed.

Role in hair cycling

At the end of telogen, Wnt ligands secreted by the dermal papilla activate beta-catenin signalling in bulge stem cells and secondary hair germ cells. This activation is required for the transition from telogen to anagen — mice with DP-specific Wnt deletion fail to enter anagen, demonstrating the pathway's necessity rather than mere contribution.

During anagen, sustained Wnt activity maintains matrix cell proliferation and hair fibre production. Experimental augmentation of Wnt signalling (via beta-catenin stabilisation or GSK-3β inhibition) extends anagen and increases hair shaft diameter in animal models.

Investigational targeting strategies

GSK-3β inhibitors: Small molecules that inhibit the beta-catenin destruction complex, allowing beta-catenin to accumulate even without upstream Wnt ligand binding. Topical formulations have shown hair growth in preclinical models; human trials are underway or in preparation.

SCUBE3: A secreted signalling protein identified as an activator of Wnt pathway activity specifically in the DP. SCUBE3 is expressed in active DP cells and can stimulate hair growth when applied to the skin in murine models. It represents a relatively follicle-specific Wnt amplification mechanism.

Prostaglandin/Wnt interactions: Research has identified interactions between prostaglandin signalling (specifically PGE2) and Wnt activity in the follicle, creating potential for combination approaches.